Dangers within: DAMP responses to damage and cell death in kidney disease

Journal of the American Society of Nephrology

Volumn 22, Issue 3, 2011, Pages 416-425

  Rosin, Diane L ^a,b   Okusa, Mark D ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 4;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DAMAGE; CHRONIC KIDNEY DISEASE; DAMAGE ASSOCIATED MOLECULAR PATTERN; DIABETIC NEPHROPATHY; GLOMERULOPATHY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR RECOGNITION; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SEPTIC SHOCK; SHORT SURVEY;

EID: 79952339508     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010040430     Document Type: Short Survey

References (159)

1. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994
2. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54: 1-13, 1989
3. Kono H, Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289, 2008 (Pubitemid 351432799)
4. Matzinger P: Friendly and dangerous signals: Is the tissue in control? Nat Immunol 8: 11-13, 2007
5. Matzinger P: The danger model: A renewed sense of self. Science 296: 301-305, 2002
6. Seong SY, Matzinger P: Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4: 469-478, 2004
7. Peter C, Wesselborg S, Lauber K, Krysko DV, Vandenabeele P: Role of attraction and danger signals in the uptake of apoptotic and necrotic cells and its immunological outcome. In: Phagocytosis of Dying Cells: From Molecular Mechanisms to Human Diseases, Berlin, Springer Science+ Business Media BV, 2009, pp 63-101
8. Xiang M, Fan J: Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med 16: 69-82, 2010
9. Foell D, Wittkowski H, Roth J: Mechanisms of disease: A "DAMP" view of inflammatory arthritis. Nat Clin Pract Rheumatol 3: 382-390, 2007
10. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P: Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 1805: 53-71, 2010
11. Srikrishna G, Freeze HH: Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11: 615-628, 2009
12. Eleftheriadis T, Lawson BR: Toll-like receptors and kidney diseases. Inflamm Allergy Drug Targets 8: 191-201, 2009
13. Robson MG: Toll-like receptors and renal disease. Nephron Exp Nephrol 113: e1-e7, 2009
14. Shirali AC, Goldstein DR: Tracking the toll of kidney disease. J Am Soc Nephrol 19: 1444-1450, 2008
15. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J: The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 6: 224-235, 2010
16. Bianchi ME: DAMPs PAM: Ps and alarmins: All we need to know about danger. J Leukocyte Biol 81: 1-5, 2007
17. Yang D, de la RG, Tewary P, Oppenheim JJ: Alarmins link neutrophils and dendritic cells. Trends Immunol 30: 531-537, 2009
18. Yang H, Tracey KJ: Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 149-156, 2001
19. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tor M, Billiar T: The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220: 60-81, 2007 (Pubitemid 350045579)
20. Bianchi ME, Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46, 2007 (Pubitemid 350045574)
21. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: Endogenous danger signaling. Mol Med 14: 476-484, 2008
22. Bianchi ME: HMGB1 loves company. J Leukocyte Biol 86: 573-576, 2009
23. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002 (Pubitemid 34773774)
24. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMGB-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999 (Pubitemid 29329996)
25. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 1135-1143, 2005 (Pubitemid 40524681)
26. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ: High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukocyte Biol 81: 59-66, 2007 (Pubitemid 46021253)
27. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D, Schmidt AM: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995
28. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924, 2006
29. Schneider M, Hansen JL, Sheikh SP: S100A4: A common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med 86: 507-522, 2008
30. Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukocyte Biol 81: 28-37, 2007 (Pubitemid 46021248)
31. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999 (Pubitemid 29375048)
32. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA: Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 170: 3233-3242, 2003 (Pubitemid 36302201)
33. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J: The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukocyte Biol 86: 557-566, 2009
34. van Eden W, van der Zee R, Prakken B: Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 5: 318-330, 2005
35. Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2: 185-194, 2002
36. Tsan MF, Gao B: Heat shock proteins and immune system. J Leukocyte Biol 85: 905-910, 2009
37. Li Z, Menoret A, Srivastava P: Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14: 45-51, 2002 (Pubitemid 34085106)
38. Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, Hizuta A, Tanaka N, Srivastava PK, Nakayama E: Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 162: 1303-1309, 1999 (Pubitemid 29306999)
39. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955, 2001 (Pubitemid 32946067)
40. Ramasamy R, Yan SF, Schmidt AM: RAGE: Therapeutic target and biomarker of the inflammatory response: The evidence mounts. J Leukocyte Biol 86: 505-512, 2009
41. Yan SF, Ramasamy R, Schmidt AM: Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79: 1379-1386, 2010
42. Yan SF, Ramasamy R, Schmidt AM: Receptor for AGE (RAGE) and its ligands: Cast into leading roles in diabetes and the inflammatory response. J Mol Med 87: 235-247, 2009
43. Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E: TLR9 and the recognition of self and non-self nucleic acids. Ann N Y Acad Sci 1082: 31-43, 2006 (Pubitemid 44955446)
44. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ: Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 119: 305-314, 2009
45. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM: Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 167: 2602-2607, 2001 (Pubitemid 32768888)
46. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107, 2010
47. Calfee CS, Matthay MA: Clinical immunology: Culprits with evolutionary ties. Nature 464: 41-42, 2010
48. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521, 2003 (Pubitemid 37237047)
49. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241, 2006 (Pubitemid 43372104)
50. Martinon F, Mayor A, Tschopp J: The Inflammasomes: Guardians of the Body. Annu Rev Immunol 27: 229-265, 2009
51. Liu-Bryan R: Intracellular innate immunity in gouty arthritis: Role of NALP3 inflammasome. Immunol Cell Biol 88: 20-23, 2009
52. Shi Y, Galusha SA, Rock KL: Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 176: 3905-3908, 2006 (Pubitemid 44264366)
53. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins: Natural peptide antibiotics of human neutrophils. J Clin Invest 76: 1427-1435, 1985 (Pubitemid 16193690)
54. Zaiou M, Gallo R: Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 80: 549-561, 2002
55. Masson PL, Heremans JF, Schonne E: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med 130: 643-658, 1969
56. Schaefer L: Extracellular matrix molecules: Endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 10: 185-190, 2010
57. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Grone HJ, Schaefer L: Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll and P2X receptors. J Biol Chem 284: 24035-24048, 2009
58. Sato S, St-Pierre C, Bhaumik P, Nieminen J: Galectins in innate immunity: Dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol Rev 230: 172-187, 2009
59. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M, Liu FT: Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 165: 2156-2164, 2000 (Pubitemid 30643165)
60. Fredholm BB: Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14: 1315-1323, 2007
61. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC: Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112: 358-404, 2006 (Pubitemid 44486409)
62. Trautmann A: Extracellular ATP in the immune system: More than just a "danger signal." Sci Signal 2: pe6, 2009
63. Di Virgilio F: Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 28: 465-472, 2007
64. Blackburn MR, Vance CO, Morschl E, Wilson, CN: Adenosine receptors and inflammation. Handb Exp Pharmacol: 215-269, 2009
65. Schenk H, Vogt M, Droge W, Schulze-Osthoff K: Thioredoxin as a potent costimulus of cytokine expression. J Immunol 156: 765-771, 1996 (Pubitemid 26028936)
66. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Ghezzi P: Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189: 1783-1789, 1999 (Pubitemid 29272695)
67. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Knchler AM: Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 30: 227-233, 2009
68. Serafini-Cessi F, Malagolini N, Cavallone D: Tamm-Horsfall glycoprotein: Biology and clinical relevance. Am J Kidney Dis 42: 658-676, 2003 (Pubitemid 37187366)
69. Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL: Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 76: 89-96, 2009
70. Ling XB, Sigdel TK, Lau K, Ying L, Lau I, Schilling J, Sarwal, MM: Integrative Urinary Peptidomics in Renal Transplantation Identifies Biomarkers for Acute Rejection. J Am Soc Nephrol 21: 646-653, 2010
71. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, Jennings P: Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant 25: 1896-1903, 2010
72. Saemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von GA, von AU, Horl WH, Zlabinger GJ: Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 115: 468-475, 2005 (Pubitemid 40385489)
73. El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC: Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 295: F534-F544, 2008
74. Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukocyte Biol 76: 514-519, 2004
75. Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19: 3-10, 2007
76. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876-886, 2005 (Pubitemid 41598688)
77. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388, 2010
78. Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H: Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: Structure, function and expression. Biochem J 396: 109-115, 2006 (Pubitemid 43764502)
79. Santilli F, Vazzana N, Bucciarelli LG, Davi G: Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Curr Med Chem 16: 940-952, 2009
80. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G: The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10: 241-247, 2009
81. Lamkanfi M, Dixit VM: Inflammasomes: Guardians of cytosolic sanctity. Immunol Rev 227: 95-105, 2009
82. Schroder K, Zhou R, Tschopp J: The NLRP3 inflammasome: A sensor for metabolic danger? Science 327: 296-300, 2010
83. Iwasaki A, Medzhitov R: Regulation of adaptive immunity by the innate immune system. Science 327: 291-295, 2010
84. Chun KH, Seong SY: CD14 but not MD2 transmit signals from DAMP. Int Immunopharmacol 10: 98-106, 2010
85. Chen GY, Tang J, Zheng P, Liu Y: CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323: 1722-1725, 2009
86. Liu Y, Chen GY, Zheng P: CD24-Siglec G/10 discriminates danger from pathogen-associated molecular patterns. Trends Immunology 30: 557-561, 2009
87. Bianchi ME, Manfredi AA: Immunology: Dangers in and out. Science 323: 1683-1684, 2009
88. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukocyte Biol 81: 67-74, 2007 (Pubitemid 46021254)
89. Rubartelli A, Lotze MT: Inside, outside, upside down: Damage-associated molecularpattern molecules (DAMPs) and redox. Trends Immunol 28: 429-436, 2007 (Pubitemid 47444554)
90. Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A: DAMPs and inflammatory processes: The role of redox in the different outcomes. J Leukocyte Biol 86: 549-555, 2009
91. Iwata A, Morgan-Stevenson V, Schwartz B, Liu L, Tupper J, Zhu X, Harlan J, Winn R: Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PLoS ONE 5: e9103, 2010
92. Goligorsky MS: Immune system in renal injury and repair: Burning the candle from both ends? Pharmacol Res 58: 122-128, 2008
93. Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler DF: Formation and function of Weibel-Palade bodies. J Cell Sci 121: 19-27, 2008 (Pubitemid 351265699)
94. Kuo MC, Patschan D, Patschan S, Cohen- Gould L, Park HC, Ni J, Addabbo F, Goligorsky MS: Ischemia-induced exocytosis of Weibel-Palade bodies mobilizes stem cells. J Am Soc Nephrol 19: 2321-2330, 2008
95. Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS: Uric Acid Heralds Ischemic Tissue Injury to Mobilize Endothelial Progenitor Cells. J Am Soc Nephrol 18: 1516-1524, 2007 (Pubitemid 46717518)
96. Goligorsky MS, Patschan D, Kuo MC: Weibel-Palade bodies: Sentinels of acute stress. Nat Rev Nephrol 5: 423-426, 2009
97. Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-F659, 2005 (Pubitemid 41324185)
98. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP: Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53: 51-58, 2009
99. Li L, Okusa MD: Blocking the immune response in ischemic acute kidney injury: The role of adenosine 2A agonists. Nat Clin Pract Nephrol 2: 432-444, 2006 (Pubitemid 44174535)
100. Lu CY, Hartono J, Senitko M, Chen J: The inflammatory response to ischemic acute kidney injury: A result of the "right stuff" in the "wrong place"? Curr Opin Nephrol Hypertens 16: 83-89, 2007
101. Mkaddem SB, Werts C, Goujon JM, Bens M, Pedruzzi E, Ogier-Denis E, Vandewalle A: Heat shock protein gp96 interacts with protein phosphatase 5 and controls Toll-like receptor 2 (TLR2)-mediated activation of extracellular signal-regulated kinase (ERK) 1/2 in post-hypoxic kidney cells. J Biol Chem 284: 12541-12549, 2009
102. Harrison EM, Sharpe E, Bellamy CO, McNally SJ, Devey L, Garden OJ, Ross JA, Wigmore SJ: Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol 295: F397-F405, 2008
103. Zhang PL, Lun M, Schworer CM, Blasick TM, Masker KK, Jones JB, Carey DJ: Heat shock protein expression is highly sensitive to ischemia-reperfusion injury in rat kidneys. Annals Clin Lab Sci 38: 57-64, 2008 (Pubitemid 351323726)
104. Park SW, Chen SWC, Kim M, D'Agati VD, Lee HT: Human heat shock protein 27-overexpressing mice are protected against acute kidney injury after hepatic ischemia and reperfusion. Am J Physiol Renal Physiol 297: F885-F894, 2009
105. Chen SWC, Kim M, Kim M, Song JH, Park SW, Wells D, Brown K, Belleroche JD, D'Agati VD, Lee HT: Mice that overexpress human heat shock protein 27 have increased renal injury following ischemia reperfusion. Kidney Int 75: 499-510, 2008
106. Chung KY, Park JJ, Kim YS: The role of high mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc 40: 2136-2138, 2008
107. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117: 2847-2859, 2007 (Pubitemid 47529615)
108. Bonventre JV: Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. Nephrol Dial Transplant 24: 3265-3268, 2009
109. Ichimura T, Asseldonk EJP, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV: Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 118: 1657-1668, 2008 (Pubitemid 351632370)
110. Tanji NOZO, Markowitz GS, Fu CAIF, Kislinger THOM, Taguchi AKIH, Pischetsrieder MONI, Stern DAVI, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666, 2000
111. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38: S100-S106, 2001 (Pubitemid 32927622)
112. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy. Am J Pathol 162: 1123-1137, 2003 (Pubitemid 36350658)
113. Cooper ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17: 31S-38S, 2004
114. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H: RAGE control of diabetic nephropathy in a mouse model: Effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55: 2510-2522, 2006 (Pubitemid 44871151)
115. Tan AL, Forbes JM, Cooper ME: AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143, 2007 (Pubitemid 46550311)
116. Sourris KC, Forbes JM: Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy: Are these receptors valid therapeutic targets? Curr Drug Targets 10: 42-50, 2009
117. D'Agati V, Yan SF, Ramasamy R, Schmidt AM: RAGE, glomerulosclerosis and proteinuria: Roles in podocytes and endothelial cells. Trends Endocrinol Metab 21: 50-56, 2010
118. Coughlan MT, Mibus AL, Forbes JM: Oxidative stress and advanced glycation in diabetic nephropathy. Ann NY Acad Sci 1126: 190-193, 2008 (Pubitemid 351589280)
119. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM: RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20: 742-752, 2009
120. Chen SC, Guh JY, Hwang CC, Chiou SJ, Lin TD, Ko YM, Huang JS, Yang YL, Chuang LY: Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts. J Cell Biochem 109: 38-48, 2010
121. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins: A Novel Pathway for Inflammatory Cell Recruitment. J Exp Med 198: 1507-1515, 2003 (Pubitemid 37467165)
122. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi, S-i, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001 (Pubitemid 32656250)
123. Cai W, He JC, Zhu L, Lu C, Vlassara H: Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A 103: 13801-13806, 2006 (Pubitemid 44413988)
124. Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 1126: 46-52, 2008 (Pubitemid 351589317)
125. Guo J, Ananthakrishnan R, Qu W, Lu Y, Reiniger N, Zeng S, Ma W, Rosario R, Yan SF, Ramasamy R, D'Agati V, Marie Schmidt A: RAGE Mediates Podocyte Injury in Adriamycin-induced Glomerulosclerosis. J Am Soc Nephrol 19: 961-972, 2008
126. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Mazzitelli G, Cordone S, Pesce C, Pugliese F, Pricci F, Pugliese G: Advanced lipoxidation end-products mediate lipid-induced glomerular injury: Role of receptor-mediated mechanisms. J Pathol 218: 360-369, 2009
127. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, Stoelcker B, Liu G, Grone HJ, Kramer BK, Alpers CE: TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19: 704-713, 2008
128. Lang A, Benke D, Eitner F, Engel D, Ehrlich S, Breloer M, Hamilton-Williams E, Specht S, Hoerauf A, Floege J, von BA, Kurts C: Heat shock protein 60 is released in immune-mediated glomerulonephritis and aggravates disease: In vivo evidence for an immunologic danger signal. J Am Soc Nephrol 16: 383-391, 2005 (Pubitemid 41725133)
129. Sadlier DM, Ouyang X, McMahon B, Mu W, Ohashi R, Rodgers K, Murray D, Nakagawa T, Godson C, Doran P, Brady HR, Johnson RJ: Microarray and bioinformatic detection of novel and established genes expressed in experimental anti-Thy1 nephritis. Kidney Int 68: 2542-2561, 2005 (Pubitemid 43251000)
130. Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S: High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clinical Practice 108: c194-c201, 2008 (Pubitemid 351588112)
131. Frosch M, Vogl T, Waldherr R, Sorg C, Sunderkotter C, Roth J: Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J Leukocyte Biol 75: 198-206, 2004 (Pubitemid 38174575)
132. Vidyasagar A, Reese S, Acun Z, Hullett D, Djamali A: HSP27 is involved in the pathogenesis of kidney tubulointerstitial fibrosis.AmJ Physiol Renal Physiol 295: F707-F716, 2008
133. Lange-Sperandio B, Schimpgen K, Rodenbeck B, Chavakis T, Bierhaus A, Nawroth P, Thornhill B, Schaefer F, Chevalier RL: Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int 69: 81-88, 2006 (Pubitemid 43117742)
134. Kypreou KP, Kavvadas P, Karamessinis P, Peroulis M, Alberti A, Sideras P, Psarras S, Capetanaki Y, Politis PK, Charonis AS: Altered expression of calreticulin during the development of fibrosis. Proteomics 8: 2407-2419, 2008
135. Schaefer L, Macakova K, Raslik I, Micegova M, Grone HJ, Schonherr E, Robenek H, Echtermeyer FG, Grassel S, Bruckner P, Schaefer RM, Iozzo RV, Kresse H: Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160: 1181-1191, 2002 (Pubitemid 34224603)
136. Kim J, Seok YM, Jung KJ, Park KM: Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol 297: F461-F470, 2009
137. Pan HF, Wu GC, Li WP, Li XP, Ye DQ: High mobility group box 1: A potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep 37: 1191-1195, 2010
138. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De MF, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE. J Exp Med 205: 3007-3018, 2008
139. Jiang W, Pisetsky DS: Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Annals Rheum Dis 67: 727-728, 2008 (Pubitemid 351571946)
140. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C: Pathogenic anti- DNA antibodies modulate gene expression in mesangial cells: Involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 121: 61-73, 2008
141. Iwata Y, Furuichi K, Sakai N, Yamauchi H, Shinozaki Y, Zhou H, Kurokawa Y, Toyama T, Kitajima S, Okumura T, Yamada S, Maruyama I, Matsushima K, Kaneko S, Wada T: Dendritic cells contribute to autoimmune kidney injury in MRL-Faslpr mice. J Rheumatol 36: 306-314, 2009
142. Mortensen ES, Fenton KA, Rekvig OP: Lupus nephritis: The central role of nucleosomes revealed. Am J Pathol 172: 275-283, 2008 (Pubitemid 351282015)
143. Mortensen ES, Rekvig OP: Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20: 696-704, 2009
144. Rao DA, Pober JS: Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 28: 229-248, 2008
145. Alegre ML, Goldstein DR, Chong AS: Toll-like receptor signaling in transplantation. Curr Opin Organ Transplant 13: 358-365, 2008
146. Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, Lin M, Walsh L, Vella J, Fischereder M, Kramer BK, Colvin RB, Heeger PS, Murphy BT, Schroppel B: Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 106: 3390-3395, 2009
147. Wang S, Schmaderer C, Kiss E, Schmidt C, Bonrouhi M, Porubsky S, Gretz N, Schaefer L, Kirschning CJ, Popovic ZV, Grone HJ: Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech 3: 92-103, 2010
148. Eikmans M, Roos-van Groningen MC, Sijpkens YW, Ehrchen J, Roth J, Baelde HJ, Bajema IM, de Fijter JW, de HE, Bruijn JA: Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. J Am Soc Nephrol 16: 3771-3786, 2005 (Pubitemid 46211301)
149. Wu TH, Hsieh SC, Li KJ, Wu CH, Yu CL, Yang AH, Tsai CY: Altered glycosylation of Tamm-Horsfall glycoprotein derived from renal allograft recipients leads to changes in its biological function. Transpl Immunol 18: 237-245, 2008
150. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ: High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 14: 109-115, 2008 (Pubitemid 351481841)
151. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J: Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. ClinJ Am Soc Nephrol 3: 691-698, 2008
152. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B, Stenvinkel P: Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 180: 333-340, 2005 (Pubitemid 41072904)
153. Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, Tesar V, Zima T: Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22: 2020-2026, 2007 (Pubitemid 47244776)
154. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S, Zima T: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47: 406-411, 2006 (Pubitemid 43255173)
155. Leemans JC, Butter LM, Pulskens WP, Teske GJ, Claessen N, van der PT, Florquin S: The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One 4: e5704, 2009
156. Musial K, Szprynger K, Szczepanska M, Zwolinska D: The heat shock protein profile in children with chronic kidney disease. Peritoneal Dialysis International 30: 227-232, 2010
157. Crocker PR, Paulson JC, Varki A: Siglecs and their roles in the immune system. Nat Rev Immunol 7: 255-266, 2007 (Pubitemid 46480955)
158. Liu Y, Zheng P: CD24: A genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol 28: 315-320, 2007 (Pubitemid 46963136)
159. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT: The NALP3 inflammasome is involved in the innate immune response to amyloid-[beta]. Nat Immunol 9: 857-865, 2008